Europe’s healthcare leaders continue to feel the pressure from workforce gaps, tight budgets and climate-change threats. They are also facing the challenges of antimicrobial resistance (AMR) and the increasing expectation of patients to receive personalised treatment. How can healthcare leaders find a balance between planning and investing for the long-term while addressing short term issues and ensuring that patient care and safety remain at the forefront of their strategies?
This two day summit is designed to prepare leaders with insight and strategies to tackle these challenges and embrace the opportunities in the future of healthcare, with a focus on digital health, health economics, sustainability and inclusivity. There will also be a new focus on AI at this year’s summit, with a full day dedicated to AI in Health.
Future of Health Europe will convene public, private and civil sector leaders across health and technology to build towards universally excellent healthcare outcomes. Policymakers, healthcare providers, payers, academics and scientists will come together with leaders from industry, technology experts, innovators and entrepreneurs, patient associations, charities and finance.
Tuesday, November 26th
Wednesday, November 27th
Wednesday, November 27th
Commissioner for health and food safety, European Commission
As European Commissioner for Health and Food Safety, Stella Kyriakides has been leading the Commission’s work on the public health response to COVID-19.
Commissioner Kyriakides is responsible for a number of initiatives in the area of health aiming to establish a strong European Health Union. These include Europe’s Beating Cancer Plan, the implementation of the EU Pharmaceutical Strategy, the proposal for a European Health Data Space, overseeing the establishment of the European Health Preparedness and Response Authority and the operationalisation of the EU4Health Programme. She is also leading Commission efforts to develop a new comprehensive approach to mental health policy.
Commissioner Kyriakides is also responsible for the ‘Farm to Fork’ strategy for sustainable food, covering every step in the transformation of the food chain from production to consumption. Her responsibilities include animal welfare, food safety and animal health as well as leading the work to protect plant health and reducing dependency on pesticides.
Since February 2022, Commissioner Kyriakides has been at the forefront of EU efforts to support Ukraine and its people in the area of health, including by supporting the protection of the physical and mental health of Ukrainian refugees arriving in Member States.
In 2006-2019, she was elected to the Cyprus Parliament for the Democratic Rally party, of which she was the Vice-President for ten years.
In 2011, she was appointed Head of the Cyprus Delegation to the Parliamentary Assembly of the Council of Europe (PACE).
In 2017, she was elected President of the PACE, the fourth woman to hold this position in the history of the Assembly.
She has been an active advocate on patients rights, and on the rights of cancer patients, founding the first Cypriot breast cancer organisation Europa Donna Cyprus, for which she served as President for over 15 years. She was elected President to the European Breast Cancer Coalition Europa Donna, and served on numerous European patient advocacy and scientific boards.
She is the recipient of numerous awards from her community service in Cyprus and globally.
Consultant pulmonologist and former alternate minister, Ministry of Health, Greece
Consultant pulmonologist and former alternate minister, Ministry of Health, Greece
Mina Gaga is a pulmonologist who has served as assistant professor at Athens University and medical director at Sotiria Chest Diseases Hospital in Athens. Her research focuses on asthma, particularly severe asthma but also high-quality patient care. Dr Gaga has served as secretary-general and later president of the European Respiratory Society, secretary of the European Board of Accreditation in Pneumology, adviser to the World Health Organisation, and executive committee member of the Global Alliance against Chronic Respiratory Diseases (GARD). She currently serves on the standing committee of the WHO Regional Committee for Europe. For the past two years she has served as alternate minister of health in Greece.
Member, European Parliament and member of the SANT Committee
István Ujhelyi is a Hungarian politician who has served as a Member of the European Parliament since 2014 in the Progressive Alliance of Socialists and Democrats. He is vice-chair of the Committee on Tourism and Transportation (TRAN) and substitute member of the Committee on Environment, Public Health and Food Safety (ENVI). As of this year Dr Ujhelyi is also a member of ENVI’s Subcommittee on Public Health, SANT. In 2022, together with health-care organisations and colleagues, he launched the European Health Union Network, a roundtable between organisations and the Parliament.
Regius professor of medicine, University of Oxford
Sir John Bell is Regius professor of medicine at Oxford University. He was president of the Academy of Medical Sciences from 2006 to 2011, and chaired the Office for the Strategic Co-ordination of Health Research until 2017. He has been UK Life Sciences Champion since 2011. Professor Bell co-developed and wrote the 2017 UK Life Sciences Industrial Strategy and the 2021 Life Sciences Vision, providing recommendations to the UK government on ensuring the long-term success of the life-sciences sector.
Chief executive, Office of Health Economics
Graham Cookson is chief executive of OHE, the world’s oldest independent health-economics research organisation. An econometrician by training, he focuses on health-system efficiency, policy evaluation, and pricing and reimbursement in pharmaceutical markets. Through OHE’s Change Initiative, Mr Cookson leads pioneering research programmes on sustainability and prevention. He is best known for his work on the economics of staffing and skill mix in the NHS in England, which was critical to the development of the NICE Guidelines on Safe Staffing.
Deputy managing partner, AlbionVC
Andrew Elder is lead health-care partner at AlbionVC, a UK-focused venture-capital investor. A former neurosurgeon, he focuses on medical technologies and technology-enabled services to the health-care and life-science sectors. Dr Elder has invested in sectors ranging from digital health, diagnostics and imaging to machine-learning applications and therapeutics, including cell and gene therapies. Before joining AlbionVC he specialised in health-care strategy at the Boston Consulting Group
Head of policy and advocacy, Women's Brain Project
Anna Dé leads policy and advocacy activities at the Women’s Brain Project. She is a global and European public-affairs professional with 23 years’ experience in international consultancy. Ms Dé’s background is in international health-care public affairs, supporting clients with multinational policy-led health-care communications and strategies, and how to best engage on health-care policy matters at international, EU and national levels.
Chief policy strategist, Tony Blair Institute for Global Change
Benedict Macon-Cooney is chief policy strategist at the Tony Blair Institute. His work focuses on harnessing the potential of technology to reform government and stimulate industries such as AI, biotech and clean tech. Mr Macon-Cooney has a background in economics, having started his career at HM Treasury, but he has also worked in leaders’ offices around the world, including the President’s Office in Rwanda.
Associate director and head of the social Europe and well-being programme, European Policy Centre
Associate director and head of the social Europe and well-being programme, European Policy Centre
Elizabeth Kuiper is associate director at the European Policy Centre, where she also heads the Social Europe and Well-being programme. Her focus is on EU health policy and social policies, linking up the EPC’s research on health care, inclusivity and gender balance, social equality and sustainability. Before joining the EPC Ms Kuiper was executive director of public affairs at the European Federation of Pharmaceutical Industries and Associations. She previously worked as attaché at the Permanent Representation of the Netherlands to the EU in Brussels, and as political adviser to the minister of health, welfare and sports in the Netherlands.
Creative director, Jennis and Olympic champion
Jessica Ennis-Hill reached the pinnacle of her career as a heptathlete in 2012, when she claimed Olympic gold. She won three world titles (in 2009, 2011 and 2015) and was European champion in 2010. Upon her retirement from athletics in 2016, Dame Jessica focused on setting up a new fem-tech business—the app Jennis—to bring the science-based knowledge she had learned as an athlete about her body, and in particular her hormones, to as many women as possible. Jennis maps a woman’s unique hormonal cycle and provides personalised daily recommendations to improve her performance, mood and health.
Government chief whip and minister of state, Department of Health, Ireland
Government chief whip and minister of state, Department of Health, Ireland
Hildegarde Naughton is Irish minister of state at the Department of the Taoiseach with special responsibility as government chief whip; and at the Department of Health with special responsibility for public health, well-being and the national drugs strategy. She was elected to represent Galway West constituency in the 2020 general election. Ms Haughton has served on several parliamentary committees including the Future of Healthcare, and Budgetary Scrutiny. She was appointed chair of the Communications, Climate Action and Environment committee in 2016. She was appointed to the Seanad (Senate) in 2013 before being elected to the Dáil (Irish Parliament) for the first time in 2016.
Group sustainability director, Bupa
Since joining Bupa in 2014, Glyn Richards has held roles in strategy and legal functions, with a particular focus on M&A, joint ventures and operations in the Middle East and Asia. He was appointed Bupa’s group director of sustainability in July 2022 and is now responsible for shaping and implementing a global, organisation-wide sustainability strategy; directing Bupa’s environment and climate action plan (including delivery of Bupa’s net-zero commitment) and embedding it into strategy, risk and operations. Mr Richards previously worked as a corporate lawyer in a City law firm, as well as at a leading bank in Austria and other regulated industries in the UK.
Chief executive, UK Health Security Agency
Jenny Harries is the first chief executive of the UK Health Security Agency. She has wide experience of clinical and public-health science and practice, as well as health-service commissioning from work in the NHS and in local, regional and national government. Having played central roles in the UK’s response to several significant public-health incidents, Professor Harries was appointed deputy chief medical officer for England in 2019 and served through the covid-19 pandemic until taking up her present role. She has previously served on the UK’s Joint Committee for Vaccination and Immunisation (JCVI) and the Expert Advisory Group on the NHS Constitution.
Case studies and tracks focussed on economics, sustainability, digital, and inclusivity
Hear from leaders in health including clinicians, policy, patient groups, industry and more
See which organisations provide their valued support to the event
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.
Bupa‘s purpose is helping people live longer, healthier, happier lives and making a better world. We are an international healthcare company serving over 38 million customers worldwide. With no shareholders, we reinvest profits into providing more and better healthcare for the benefit of current and future customers.
Royal Philips is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion, with sales and services in more than 100 countries.
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.
LifeArc is a self-funded, not-for-profit organisation, that uses expertise and financial resources to develop treatments and cures for underserved diseases as guided by patients. We break down the barriers in early translation in the UK and beyond and partner with academics, charities, patients, Pharma and Biotech to “make life science life changing”.
Cepheid is a molecular diagnostics company founded in 1996 and is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company’s solutions deliver a better way for institutions of any size to perform sophisticated molecular testing for infectious diseases and more. Through its strong molecular biology capabilities, the company is focusing on applications where accurate, fast, and actionable PCR test results are needed most, such as COVID-19, healthcare-associated infections, sexual health, critical infectious disease, virology, and oncology. The company primarily offers a multi-use diagnostic GeneXpert® system that works across more than 30 IVD tests and fully integrates and automates sample extraction, amplification, and detection — all in one cartridge. The system is suitable for use in multiple clinical settings such as hospitals, labs and point of care primary care.
Caresyntax delivers actionable insights to improve patient outcomes by using proprietary software and AI to analyze large volumes of video, audio, images, device data, data clinical and operational in and around the operating room.
Kry is Europe’s leading digital-first healthcare provider with a mission to provide better access and efficient care for everyone. Since launching in early 2015, Kry has provided more than 200 million patient interactions throughout Europe. Headquartered in Stockholm, Kry’s 3,000+ clinicians and 1,000 employees are committed to transforming how patients access high quality healthcare. Combining its technology with its network of online healthcare professionals, Kry enables and directs patients to the right care in the right setting — whether that’s in-person at one of its clinics or online via its website and app — creating a more sustainable and resource-efficient healthcare system. Kry operates in Sweden, Norway, France, the UK and Germany. In the UK and France, Kry trades as Livi.
Owkin is an AI biotechnology company on a mission to find the right treatment for every patient. By understanding complex biology through AI, we identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. We use federated data access to unlock valuable insights from patient data while protecting patient privacy and securing proprietary data. We integrate the best of human and artificial intelligence to answer the research questions challenging biopharma and academic researchers. Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).
Ellipses Pharma is a global drug development company headquartered in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection, the expertise of a Scientific Affairs Group, which comprises more than 250 leading oncologists and an uninterrupted funding flow to minimise the time it takes to advance lead products through clinical trials and reach patients.
Please submit the form and we will reach out to you with more information.
Thank you for submitting your details. A member of our team will reach out to you at earliest.
Please submit the form and we will reach out to you with more information.
Thank you for submitting your details. A member of our team will reach out to you at earliest.
Please submit the form and we will reach out to you with more information.
Thank you for showing interest in the event. We will reach out to you with more information on the registration process.
Please submit the form and we will reach out to you with more information.
Thank you for showing interest in the event. We will reach out to you with more information on the registration process.